MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 407226 | Name: EPZ015666 (GSK3235025)
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

EPZ015666, also known as GSK3235025, is a potent and selective and orally active PRMT5 inhibitor with a half-maximal inhibitory concentration (IC50) of 22 nM and broad selectivity against a panel of other histone methyltransferases. Treatment of MCL cell lines with EPZ015666 led to inhibition of SmD3 methylation and cell death, with IC50 values in the nanomolar range. Oral dosing with EPZ015666 demonstrated dose-dependent antitumor activity in multiple MCL xenograft models. EPZ015666 represents a validated chemical probe for further study of PRMT5 biology and arginine methylation in cancer and other diseases.

Chemical Structure

EPZ015666 (GSK3235025)
EPZ015666 (GSK3235025)
CAS#1616391-65-1

Theoretical Analysis

MedKoo Cat#: 407226

Name: EPZ015666 (GSK3235025)

CAS#: 1616391-65-1

Chemical Formula: C20H25N5O3

Exact Mass: 383.1957

Molecular Weight: 383.45

Elemental Analysis: C, 62.65; H, 6.57; N, 18.26; O, 12.52

Price and Availability

Size Price Availability Quantity
5mg USD 90.00 Ready to ship
10mg USD 150.00 Ready to ship
25mg USD 250.00 Ready to ship
50mg USD 450.00 Ready to ship
100mg USD 650.00 Ready to ship
200mg USD 1,050.00 Ready to ship
500mg USD 2,150.00 Ready to ship
1g USD 3,250.00 Ready to ship
2g USD 5,650.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
EPZ015666; EPZ-015666; EPZ 015666; GSK3235025; GSK-3235025; GSK 3235025.
IUPAC/Chemical Name
(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(oxetan-3-ylamino)pyrimidine-4-carboxamide
InChi Key
ZKXZLIFRWWKZRY-KRWDZBQOSA-N
InChi Code
InChI=1S/C20H25N5O3/c26-17(10-25-6-5-14-3-1-2-4-15(14)9-25)8-21-20(27)18-7-19(23-13-22-18)24-16-11-28-12-16/h1-4,7,13,16-17,26H,5-6,8-12H2,(H,21,27)(H,22,23,24)/t17-/m0/s1
SMILES Code
O=C(C1=NC=NC(NC2COC2)=C1)NC[C@H](O)CN3CC4=C(C=CC=C4)CC3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
EPZ015666 (GSK3235025) is an orally available inhibitor of PRMT5 with an IC50 of 22 nM.
In vitro activity:
The impact of EPZ015666 on T-cell proliferation and viability was checked. EPZ015666 reduced T-cell proliferation with increasing concentrations. Cells were more sensitive to this inhibitor as suppression was already detectable at much lower doses, but even the highest tested concentration was less effective compared with MTA (Fig. 1E). Freshly isolated human CD8+ T cells were stimulated with autologous Mart-1 peptide-loaded mDCs in the presence or absence of 10 μmol/L EPZ015666. The frequency of Mart-1–specific CTLs was monitored by Mart-1 multimer staining over 18 days. No Mart-1+ cells could be detected in the presence of EPZ015666 after 18 days (Fig. 2D). In addition, there was a stronger reduction of Mart-1+ CTLs after 18 days compared with MTA-treated cells (Fig. 2B and E). Reference: Mol Cancer Ther. 2020 Feb;19(2):409-419. http://mct.aacrjournals.org/cgi/pmidlookup?view=long&pmid=31712395
In vivo activity:
EPZ015666 is orally bioavailable and amenable to in vivo studies. 21-d efficacy studies were performed in severe combined immunodeficiency (SCID) mice bearing subcutaneous Z-138 and Maver-1 xenografts, with twice-daily (BID) oral dosing on four dose groups: 25, 50, 100 and 200 mg per kilogram of body weight (mg kg−1). After 21 d of continuous dosing, animals were euthanized, and blood and tissues were analyzed to determine the relationship between methylmark pharmacodynamics and tumor-growth inhibition (TGI). EPZ015666 showed dose-dependent exposure and TGI after 21 d in both MCL models (Fig. 4c,d). Tumors in all EPZ015666 dose groups measured on day 21 showed statistically significant differences in weight, volume and tumor growth compared to vehicle-treated tumors. EPZ015666 was well tolerated in all three models, with minimal bodyweight loss in the 200 mg kg−1 dose group and no other clinical observations (Supplementary Fig. 16). To measure in vivo target inhibition, a highly quantitative SDMA ELISA was developed to allow for higher throughput and to complement the SDMA western blot. In the SDMA ELISA, Z-138 xenograft tumors collected on day 21 showed dose-dependent changes of >40% and >95% inhibition (>48% and >87% for Maver-1 tumors at day 21; >66% and >95% for Granta-519 tumors at day 18) of the methyl mark achieved at the lowest dose and highest dose, respectively (Fig. 4e,f and Supplementary Figs. 17–22). Reference: Nat Chem Biol. 2015 Jun;11(6):432-7. https://doi.org/10.1038/nchembio.1810
Solvent mg/mL mM
Solubility
DMSO 76.0 198.21
Ethanol 39.0 101.71
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 383.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
1. Chan-Penebre E, Kuplast KG, Majer CR, Boriack-Sjodin PA, Wigle TJ, Johnston LD, Rioux N, Munchhof MJ, Jin L, Jacques SL, West KA, Lingaraj T, Stickland K, Ribich SA, Raimondi A, Scott MP, Waters NJ, Pollock RM, Smith JJ, Barbash O, Pappalardi M, Ho TF, Nurse K, Oza KP, Gallagher KT, Kruger R, Moyer MP, Copeland RA, Chesworth R, Duncan KW. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol. 2015 Jun;11(6):432-7. doi: 10.1038/nchembio.1810. Epub 2015 Apr 27. PMID: 25915199. 2. Strobl CD, Schaffer S, Haug T, Völkl S, Peter K, Singer K, Böttcher M, Mougiakakos D, Mackensen A, Aigner M. Selective PRMT5 Inhibitors Suppress Human CD8+ T Cells by Upregulation of p53 and Impairment of the AKT Pathway Similar to the Tumor Metabolite MTA. Mol Cancer Ther. 2020 Feb;19(2):409-419. doi: 10.1158/1535-7163.MCT-19-0189. Epub 2019 Nov 11. PMID: 31712395.
In vivo protocol:
1. Chan-Penebre E, Kuplast KG, Majer CR, Boriack-Sjodin PA, Wigle TJ, Johnston LD, Rioux N, Munchhof MJ, Jin L, Jacques SL, West KA, Lingaraj T, Stickland K, Ribich SA, Raimondi A, Scott MP, Waters NJ, Pollock RM, Smith JJ, Barbash O, Pappalardi M, Ho TF, Nurse K, Oza KP, Gallagher KT, Kruger R, Moyer MP, Copeland RA, Chesworth R, Duncan KW. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol. 2015 Jun;11(6):432-7. doi: 10.1038/nchembio.1810. Epub 2015 Apr 27. PMID: 25915199.
1: Rioux N, Duncan KW, Lantz RJ, Miao X, Chan-Penebre E, Moyer MP, Munchhof MJ, Copeland RA, Chesworth R, Waters NJ. Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor. Xenobiotica. 2015 Aug 21:1-10. [Epub ahead of print] PubMed PMID: 26294260. 2: Rioux N, Duncan KW, Lantz RJ, Miao X, Chan-Penebre E, Moyer MP, Munchhof MJ, Copeland RA, Chesworth R, Waters NJ. Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor. Xenobiotica. 2015 Jul 31:1-10. [Epub ahead of print] PubMed PMID: 26228443. 3: Chan-Penebre E, Kuplast KG, Majer CR, Boriack-Sjodin PA, Wigle TJ, Johnston LD, Rioux N, Munchhof MJ, Jin L, Jacques SL, West KA, Lingaraj T, Stickland K, Ribich SA, Raimondi A, Scott MP, Waters NJ, Pollock RM, Smith JJ, Barbash O, Pappalardi M, Ho TF, Nurse K, Oza KP, Gallagher KT, Kruger R, Moyer MP, Copeland RA, Chesworth R, Duncan KW. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol. 2015 Jun;11(6):432-7. doi: 10.1038/nchembio.1810. Epub 2015 Apr 27. PubMed PMID: 25915199.